Amgen to trim workforce by up to 14%

Share this article:

Amgen announced yesterday that it would reduce company staff by up to 14% due to lower Aranesp sales.

Sales of Amgen's kidney disease-related and chemotherapy-induced anemia Aranesp fell 19% to $578 million in the second quarter from $713 million a year earlier.

"It's the first time in our 27-year history we've had to restructure," Kevin Sharer, Amgen's CEO told The Wall Street Journal. "…Virtually any company with any scale has gone through this kind of event. It's our turn," he said.

Amgen employees were expected to receive a video on their desktops today detailing the restructuring plan.

Sharer has publically rejected analysts' calls for a sales force consolidation, stating the force was already lean enough and was warranted due to its specialization in nephrology and oncology.

Amgen did not immediately return MM&M's call seeking more information on the areas of the company affected by the announced cuts.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.